Skip to main content
Top
Published in: Drug Safety 10/2014

01-10-2014 | Special Article

Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum

Authors: Jürgen Beckmann, Ulrich Hagemann, Priya Bahri, Andrew Bate, Ian W. Boyd, Gerald J. Dal Pan, Brian D. Edwards, I. Ralph Edwards, Kenneth Hartigan-Go, Marie Lindquist, John McEwen, Yola Moride, Sten Olsson, Shanthi N. Pal, Rachida Soulaymani-Bencheikh, Marco Tuccori, Claudia P. Vaca, Ian C. K. Wong

Published in: Drug Safety | Issue 10/2014

Login to get access

Excerpt

The importance of pharmacovigilance (PV) for safe medicines and their safe use has increasingly been recognised during the last few years [1]. PV has been subject of intense research and regulation. In particular, it has earned more and more importance and attention in low-resource countries. This is largely due to the globalisation of trade and the availability of new, highly effective but potentially harmful chemical medicinal products in those parts of the world where traditional treatments, in particular herbal or other complementary remedies, used to prevail. A plethora of publications, guidelines and information about newly observed or further investigated adverse drug reactions (ADRs) from all over the world creates a growing burden for people working with medicines or patients to keep abreast of this development. Largely due to the global availability of information through the Internet, patients are nowadays more and more critical and often concerned about, or even frightened of, potential ADRs of their medicines. This poses an additional demand on the up-to-date capacities of their doctors and other healthcare professionals (HCPs). A particular challenge is the multidisciplinary character of PV which requires know-how in topics as different as molecular mechanisms of ADRs, clinical medicine, pharmacoepidemiology, information technology, pharmaceutical manufacturing, legal aspects, public health situations on various levels, and traditions in different regions of the world. Also, theoretical knowledge needs supplementing with experience and practical skills. …
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization, the Uppsala Centre for International Drug Monitoring. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization; 2002. World Health Organization, the Uppsala Centre for International Drug Monitoring. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization; 2002.
8.
go back to reference Talbot J, Aronson JK, editors. Stephens’ detection and evaluation of adverse drug reactions: principles and practice. 6th ed. Chichester: Wiley-Blackwell; 2012. Talbot J, Aronson JK, editors. Stephens’ detection and evaluation of adverse drug reactions: principles and practice. 6th ed. Chichester: Wiley-Blackwell; 2012.
9.
go back to reference Andrews E, Moore N, editors. Mann’s Pharmacovigilance. 3rd ed. Chichester: Wiley-Blackwell; 2014. Andrews E, Moore N, editors. Mann’s Pharmacovigilance. 3rd ed. Chichester: Wiley-Blackwell; 2014.
10.
go back to reference Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Chichester: Wiley-Blackwell; 2012. Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th ed. Chichester: Wiley-Blackwell; 2012.
11.
go back to reference Van Boxtel CJ, Edwards IR, Santoso B, editors. Drug benefits and risks - international textbook of clinical pharmacology. 2nd ed. Amsterdam: IOS Press; 2008. Van Boxtel CJ, Edwards IR, Santoso B, editors. Drug benefits and risks - international textbook of clinical pharmacology. 2nd ed. Amsterdam: IOS Press; 2008.
12.
go back to reference Rawlins MD. Therapeutics, evidence and decision-making. London: Hodder Arnold; 2011. Rawlins MD. Therapeutics, evidence and decision-making. London: Hodder Arnold; 2011.
13.
go back to reference Aronson JK, editor. Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 15th ed. Amsterdam: Elsevier; 2006. Aronson JK, editor. Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. 15th ed. Amsterdam: Elsevier; 2006.
14.
go back to reference Sweetman SC, editor. Martindale: the complete drug reference. 37th ed. London: Pharmaceutical Press; 2013. Sweetman SC, editor. Martindale: the complete drug reference. 37th ed. London: Pharmaceutical Press; 2013.
15.
go back to reference World Health Organization. WHO model formulary 2008. Geneva: WHO Press; 2009. World Health Organization. WHO model formulary 2008. Geneva: WHO Press; 2009.
20.
go back to reference Medicines and Health products Regulatory Authority. Good pharmacovigilance practice guide. London: Pharmaceutical Press; 2009. Medicines and Health products Regulatory Authority. Good pharmacovigilance practice guide. London: Pharmaceutical Press; 2009.
22.
go back to reference Cobert B. Cobert’s manual of drug safety and pharmacovigilance. 2nd ed. Sudbury: Jones & Bartlett; 2012. Cobert B. Cobert’s manual of drug safety and pharmacovigilance. 2nd ed. Sudbury: Jones & Bartlett; 2012.
23.
go back to reference Centre for Tropical Clinical Pharmacology and Therapeutics - University of Ghana Medical School. PV Toolkit. Available from: http://pvtoolkit.org/. Accessed 31 May 2014. Centre for Tropical Clinical Pharmacology and Therapeutics - University of Ghana Medical School. PV Toolkit. Available from: http://​pvtoolkit.​org/​. Accessed 31 May 2014.
Metadata
Title
Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum
Authors
Jürgen Beckmann
Ulrich Hagemann
Priya Bahri
Andrew Bate
Ian W. Boyd
Gerald J. Dal Pan
Brian D. Edwards
I. Ralph Edwards
Kenneth Hartigan-Go
Marie Lindquist
John McEwen
Yola Moride
Sten Olsson
Shanthi N. Pal
Rachida Soulaymani-Bencheikh
Marco Tuccori
Claudia P. Vaca
Ian C. K. Wong
Publication date
01-10-2014
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 10/2014
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0216-1

Other articles of this Issue 10/2014

Drug Safety 10/2014 Go to the issue